Eurobio Oncology

What is EndoPredict^®

Breast Cancer Prognostic and Chemotherapy Benefit Predictive Test

Knowing the details of your breast cancer helps you take charge of your treatment. EndoPredict is a modern molecular test that provides clear, precise information about your breast cancer. It is a nex generation test that looks at the activity of certain genes in your tumor and additional factors to estimate the risk of the cancer coming back and whether chemotherapy is likely to provide additional benefit.

EndoPredict is for women, both before and after menopause, who have early-stage, non-metastatic ER-positive, HER2-negative breast cancer, without or with up to three affected lymph nodes.

What You Get: Answers to Pressing Questions

Might chemotherapy be right for you?

EndoPredict shows your individual probability of breast cancer distant recurrence in the next 10 years if you were treated by hormone therapy alone.¹ It also shows how much chemotherapy could lower the chance of the cancer spreading or coming back in another part of the body.² As tumors treated with chemotherapy could also return, the benefits of chemotherapy may not outweigh the potential side-effects for you.

Estimated Chemotherapy Benefit at 10 Years

Some women will benefit more from chemotherapy than others – EndoPredict predicts the personalized benefit from chemotherapy for every patient to guide treatment decision making.²

Probability of Breast Cancer Spreading Outside of the Breast

EndoPredict is a highly accurate prognostic test to guide early treatment decisions, providing an individual probability of breast cancer recurrence at 10 years.^4,5

Might 5 years of hormone therapy be enough?

EndoPredict estimates your risk of breast cancer coming back within 10 years after completing 5 years of hormone therapy.³ This helps you and your doctor decide whether 5 years is enough or if extending hormone therapy may be beneficial. You receive this information before treatment begins, so you can make well-informed decisions for both now and the future.

Likelihood of Breast Cancer Recurrence Later On

EndoPredict estimates the risk of breast cancer coming back for up to 15 years. This can help to decide whether hormone therapy might be stopped after 5 years.³

How Does EndoPredict^® Work?

EndoPredict is a special genomic test that looks at the activity of 12 genes in your tumor. Genes are like tiny instruction manuals inside your cells that tell them how to grow and work. Changes in gene activity can affect how the cancer develops. By studying this “molecular fingerprint”, the test can show how your cancer is likely to act. A higher score means a higher probability the cancer could come back.¹

Genes

Genes are small sections of DNA, the material in your cells that carries your hereditary information and the instructions for how your cells work. The activity of some of these genes in your tumor cells can influence how quickly cancer grows or spreads – and how it might respond to treatment.

Genomic Test

A genomic test measures the activity of specific genes in a tumor. It helps to understand how the cancer behaves. This is different from a genetic test, which looks for inherited changes in the DNA sequence that may increase risk of developing cancer.

What Makes EndoPredict^® Different?
Thoughtful Gene Selection
Combined with Clinical-Pathological Insight

The Genes That Make the Difference

EndoPredict focuses on two important areas: genes that show how fast the tumor might grow, and genes related to hormone sensitivity.¹
By combining this information, EndoPredict provides a balanced Molecular Score based on 12 carefully selected genes – helping to better understand the risk of your cancer coming back.

Types of genes in EndoPredict

Genes that show how fast the tumor might grow (proliferation-associated genes): These genes are linked to how quickly cancer cells grow and divide. When these genes are very active, it usually means the tumor is growing faster and may have a higher risk of coming back.

Genes related to hormone sensitivity (hormone receptor-associated genes): These genes are connected to how the cancer responds to hormones like estrogen. If these genes are more
active, it often means the tumor is more sensitive to hormone therapy and tends to behave less aggressively.

EndoPredict^® doesn’t Stop at Molecular Data

Unlike other tests, EndoPredict looks at your genes together with important medical information like tumor size and lymph node status¹ to create your personal EPclin Risk Score – giving you a fuller and more reliable assessment.^4,5
It clearly shows whether your cancer is high or low risk of coming back – there’s no uncertain middle ground.¹

Your EPclin Risk Score helps you understand your risk both in the years right after treatment and much later.^1,3 It also gives guidance on whether chemotherapy is likely to be helpful for you, so you and your doctor can make the best decision together.assessment.²

What Should I Do Next?

If you have been diagnosed with early-stage ER+/HER2- breast cancer, ask your doctor about EndoPredict.

Together, you can decide if this test can help guide your treatment decisions and give you the peace of mind you deserve.

Learn More in Just a few Minutes

This short video walks you through how the test analyzes your tumor biology and combines it with clinical factors to create your personalized EPclin Risk Score – helping you and your doctor make clearer, more confident decisions about your care.

Want to Learn More at Your Own Pace?

References

Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
Buus R. et al.: Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. J Natl Cancer Inst. 2016
Sestak I. et al.: Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018